Incyte Appoints Bill Meury as President and CEO, Succeeding Hervé Hoppenot Amid Strategic Leadership Transition In a pivotal leadership transition that marks a new chapter in its corporate journey, Incyte Corporation , a leading global biopharmaceutical company, announced today the…
WuXi AppTec’s Nantong Facility Wins 2025 Architizer A+Award for Excellence in Human-Centered Industrial Design WuXi AppTec, a globally recognized provider of research, development, and manufacturing services for the pharmaceutical and life sciences industries, has proudly announced that its Nantong facility…
BeOne Medicines Receives Positive CHMP Opinion for New Film-Coated Tablet Formulation of BRUKINSA® (zanubrutinib), Paving the Way for European Market Approval BeOne Medicines Ltd. a globally operating oncology-focused biopharmaceutical company, has taken a significant step forward in expanding patient access…
Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart, an investigational immunology therapy developed by Sanofi, for the treatment…
Rebuilding Trust and Reshaping Global Health Finance: H20 Summit Lays Groundwork for G20 Health Agenda From June 19 to 20, global leaders in health and development converged in Geneva for the annual Health20 (H20) Summit. The high-level event, organized by…
Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the recipient of its 2025 North American Advance Biotech Grant, recognizing…
FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with rare and serious disorders, today announced that the U.S. Food…
Dapirolizumab Pegol Shows Disease Activity Reduction and Fatigue Improvement in SLE at EULAR 2025 UCB and Biogen today presented additional and detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel, Fc-free, anti-CD40 Ligand (anti-CD40L)…
Merck Highlights Positive Enpatoran Phase 2 WILLOW Study Data in SLE at EULAR 2025 Merck, a leading science and technology company, today presented new and detailed results from its Phase 2 WILLOW study, emphasizing the potential of its investigational oral…
EULAR 2025: Rilzabrutinib Shows Promise in IgG4-Related Disease — Reduction in Flares and Disease Activity Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor currently in clinical development, demonstrated a significant and sustained reduction in disease flares and key disease activity markers…
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health…